Literature DB >> 9649198

Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system.

T Atsumi1, M A Khamashta, O Amengual, S Donohoe, I Mackie, K Ichikawa, T Koike, G R Hughes.   

Abstract

It is known that antiphospholipid antibodies (aPL) hamper the anticoagulant activity of the protein C system, but the mechanism is still obscure. In this study, we demonstrate that anticardiolipin antibodies (not anti-protein C autoantibodies) can bind protein C via beta2-GPI, which bears their binding epitope, in a fashion dependent on negatively charged phospholipids. We studied the binding of IgG from aPL to protein C in the presence of beta2-GPI by ELISA (anti-'protein C' antibody ELISA), and compared their binding with those obtained in the absence of beta2-GPI. In the anti-'protein C' antibody ELISA system, 47% of 78 aPL+ patients had a positive titre in the presence of cardiolipin (CL) and beta2-GPI, but binding was not found in the absence of beta2-GPI. Highly significant correlations were found between the titre of anti-'protein C' antibody in the presence of beta2-GPI and that of anti-beta2-GPI antibody (r = 0.802, P = 0.0001). We further analysed the interaction between protein C, phospholipids, beta2-GPI and human aCL MoAbs established from patients with antiphospholipid syndrome. In a first set of experiments, the binding of beta2-GPI to protein C and its phospholipid dependency were investigated. Beta2-GPI bound to protein C in the presence of CL or phosphatidylserine, but not in the presence of phosphatidylcholine or phosphatidylethanolamine. In a second group of experiments, the binding of three human monoclonal aCL recognizing the cryptic epitope of beta2-GPI (virtually anti-beta2-GPI antibodies) was evaluated in the presence of cardiolipin and beta2-GPI. All three human monoclonal aCL bound to protein C in the presence of CL and beta2-GPI, whereas they did not in the absence of either beta2-GPI or CL. These data suggest that protein C could be a target of aCL by making a complex with CL and beta2-GPI, leading to protein C dysfunction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649198      PMCID: PMC1904974          DOI: 10.1046/j.1365-2249.1998.00582.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  61 in total

1.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C.

Authors:  N L Esmon; W G Owen; C T Esmon
Journal:  J Biol Chem       Date:  1982-01-25       Impact factor: 5.157

2.  Inactivation of human coagulation factor V by activated protein C.

Authors:  K Suzuki; J Stenflo; B Dahlbäck; B Teodorsson
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

3.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

Authors:  C T Esmon; W G Owen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

4.  beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface.

Authors:  T Mori; H Takeya; J Nishioka; E C Gabazza; K Suzuki
Journal:  Thromb Haemost       Date:  1996-01       Impact factor: 5.249

5.  Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Suzuki; T Sumida; T Yasuda; T Koike
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

6.  The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C.

Authors:  H M Bakker; G Tans; T Janssen-Claessen; M C Thomassen; H C Hemker; J H Griffin; J Rosing
Journal:  Eur J Biochem       Date:  1992-08-15

7.  Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding.

Authors:  E Matsuura; M Igarashi; Y Igarashi; H Nagae; K Ichikawa; T Yasuda; T Koike
Journal:  Int Immunol       Date:  1991-12       Impact factor: 4.823

8.  Beta 2-glycoprotein I deficiency and the risk of thrombosis.

Authors:  L F Bancsi; I K van der Linden; R M Bertina
Journal:  Thromb Haemost       Date:  1992-06-01       Impact factor: 5.249

9.  Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells.

Authors:  M Borrell; N Sala; C de Castellarnau; S Lopez; M Gari; J Fontcuberta
Journal:  Thromb Haemost       Date:  1992-09-07       Impact factor: 5.249

10.  Deficiency of protein C in congenital thrombotic disease.

Authors:  J H Griffin; B Evatt; T S Zimmerman; A J Kleiss; C Wideman
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  8 in total

Review 1.  Association of anticardiolipin antibodies with vascular injury: possible mechanisms.

Authors:  Y S Haviv
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Antiphospholipid antibodies and stroke.

Authors:  Stanley Tuhrim
Journal:  Curr Cardiol Rep       Date:  2004-03       Impact factor: 2.931

3.  A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C.

Authors:  Kwan-Ki Hwang; Cheng-De Yang; Weihong Yan; Jennifer M Grossman; Bevra H Hahn; Pojen P Chen
Journal:  Arthritis Rheum       Date:  2003-06

4.  Pathogenesis of Antiphospholipid Syndrome.

Authors:  Borut Bo Ic
Journal:  EJIFCC       Date:  2004-08-31

5.  Pathophysiology of Antiphospholipid Syndrome.

Authors:  David Green
Journal:  Thromb Haemost       Date:  2021-11-18       Impact factor: 6.681

Review 6.  The role of the complement system in kidney glomerular capillary thrombosis.

Authors:  Yoko Yoshida; Hiroshi Nishi
Journal:  Front Immunol       Date:  2022-09-14       Impact factor: 8.786

Review 7.  Basic mechanisms and pathogenesis of venous thrombosis.

Authors:  Charles T Esmon
Journal:  Blood Rev       Date:  2009-09       Impact factor: 8.250

8.  Antiphospholipid-related chorea.

Authors:  Silvio Peluso; Antonella Antenora; Anna De Rosa; Alessandro Roca; Gennaro Maddaluno; Vincenzo Brescia Morra; Giuseppe De Michele
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.